Tianjin Tasly Pharma out-licensed US marketing rights for compound Danshen dripping pills, a TCM for angina, to Arbor Pharma. Arbor will pay up to $23 million upfront to underwrite the US Phase III trial of Danshen. Ultimately, if Danshen is approved, Arbor will pay $50 million for Danshen rights plus 50% of its gross profit from the drug to Tasly’s US subsidiary. Tasly pointed out that Danshen is the first TCM to ever complete a US Phase III trial, though results are not published.
Source: China Biotoday
